Daily Ards Research Analysis
Analyzed 5 papers and selected 3 impactful papers.
Summary
Preclinical and translational studies highlight immune-modulatory axes (RORγt/IL-17 and circRNA signaling) that drive lung inflammation in ALI/ARDS, while a large clinical registry quantifies obesity as an independent risk factor for perioperative respiratory complications. Together, these papers map targets from bench to bedside and inform risk stratification for trauma patients undergoing emergent surgery.
Research Themes
- Th17/Treg balance and IL-17 pathway targeting in ALI/ARDS
- Noncoding RNA (circSRSF1) as biomarker and regulator of macrophage polarization
- Obesity as an independent predictor of perioperative respiratory complications in trauma
Selected Articles
1. Renshen Baidu Powder mitigates ALI by inhibiting the RORγt/IL-17 pathway and restoring the Treg/Th17 balance.
In an LPS-induced murine ALI model, RSBD attenuated lung injury by suppressing the RORγt/IL-17 axis and rebalancing Treg/Th17 immunity. Pharmacologic agonist/antagonist experiments and multi-omics profiling converged on IL-17 signaling as a key target, supporting RSBD as a multi-component immunomodulator.
Impact: This study provides mechanistic validation that targeting the RORγt/IL-17 pathway can ameliorate ALI, linking pharmacologic perturbations with immune balance and histologic improvement. It positions a traditional formula as a testable immunotherapy concept.
Clinical Implications: While preclinical, the data nominate IL-17/RORγt signaling and Treg/Th17 modulation as therapeutic axes for ALI/ARDS. Standardized RSBD-derived preparations or selective IL-17/RORγt inhibitors could be explored in early-phase trials.
Key Findings
- RSBD reduced pulmonary edema, inflammatory infiltration, and pro-inflammatory cytokines in LPS-induced ALI.
- It decreased Th17 and increased Treg cells, raising the Treg/Th17 ratio.
- RSBD suppressed RORγt and IL-17 while promoting IL-10 expression.
- RORγt inverse agonist and IL-17 neutralization replicated protection; an RORγt agonist abrogated RSBD’s effect.
- LC-MS, network pharmacology, and transcriptomics converged on IL-17 signaling as a key pathway; flavonoids/phenolics were abundant.
Methodological Strengths
- Pharmacologic validation with RORγt inverse agonist, IL-17 neutralizing antibody, and RORγt agonist.
- Integrated multi-omics (LC-MS, network pharmacology, RNA-seq) with histology and immunologic readouts.
Limitations
- Single LPS-induced ALI mouse model; generalizability to diverse ARDS etiologies is uncertain.
- Complex multi-herb formula complicates attribution and standardization; no human data.
Future Directions: Standardize RSBD constituents, define pharmacokinetics, and test IL-17/RORγt-targeted strategies (including RSBD-derived fractions) in large-animal models and phase I/II trials for ARDS.
ETHNOPHARMACOLOGICAL RELEVANCE: Acute lung injury (ALI), a life-threatening inflammatory respiratory condition often progressing to respiratory distress syndrome (ARDS), has high mortality due to dysregulated immunity and lack of targeted therapies. Renshen Baidu Powder (RSBD) is a Traditional Chinese formula from the Song Dynasty's Taiping Huimin Heji Jufang, historically used for wind-cold-damp induced respiratory disorders in patients with Qi deficiency. Although several RSBD herbs show anti-inflammatory and immune-modulating effects, its specific mechanisms and therapeutic impact on ALI remain unclear. AIM OF THIS STUDY: To investigate the therapeutic effects of RSBD on mice with lipopolysaccharide (LPS)-induced ALI and to elucidate its underlying mechanism. STUDY DESIGN AND METHODS: A model of LPS-induced ALI was developed, wherein the mice received treatment with RSBD or the positive control drug, dexamethasone. The extent of lung injury and inflammation was evaluated by determining the pulmonary wet-to-dry weight ratio, conducting histopathological staining, and measuring the levels of inflammatory cytokines. The proportions of T helper 17 (Th17) and regulatory T (Treg) cells in the spleen were quantified through flow cytometry. The activity of the retinoic acid-related orphan receptor gamma t (RORγt)/interleukin-17(IL-17) pathway was assessed using quantitative real-time PCR, western blotting, enzyme-linked immunosorbent assay and immunofluorescence. Mechanistic validation was conducted using the RORγt inverse agonist 13(RORγt13), an IL-17 neutralizing antibody (IL-17NAb) and Hexyl 4-hydroxybenzoate (HexP). Additionally, the chemical constituents, potential targets, and signaling pathways of RSBD were explored by integrating liquid chromatography-mass spectrometry (LC-MS), network pharmacology, and mRNA sequencing. RESULTS: RSBD significantly alleviated LPS-induced lung injury by reducing pulmonary edema, inflammatory cell infiltration, and pro-inflammatory cytokine release. It restored immune balance by decreasing Th17 cells and increasing Treg cells, resulting in a higher Treg/Th17 ratio. RSBD suppressed RORγt and IL-17 expression while promoting IL-10 production. Network pharmacology and transcriptomics identified the IL-17 signaling pathway as a key target of RSBD, while LC-MS revealed abundant bioactive compounds-such as flavonoids and phenolics-that might contribute to its effects. Notably, RORγt13 and IL-17NAb replicated RSBD's protective effect by suppressing the differentiation into Th17 cells and preventing lung damage. In contrast, HexP, an RORγt agonist, nullified the protective effects of RSBD, which further validated the crucial role of the RORγt/IL-17 pathway in mediating its therapeutic action. CONCLUSION: RSBD alleviated LPS-induced ALI by inhibiting the RORγt/IL-17 pathway, restoring Treg/Th17 balance, and reducing pulmonary inflammation and damage. These results provided mechanistic support for RSBD as a multi-component immunomodulatory agent for ALI treatment.
2. Role of circSRSF1 in apoptosis, inflammation, and macrophage polarization during acute respiratory distress syndrome.
circSRSF1 is upregulated in ARDS patient PBMCs and correlates with systemic inflammatory markers. Silencing circSRSF1 in LPS-stimulated RAW264.7 cells reduces apoptosis, inflammatory signaling, M1 polarization, and oxidative stress, nominating circSRSF1 as a potential biomarker and therapeutic target.
Impact: Identifies a circular RNA that links inflammatory burden with macrophage polarization in ARDS, expanding the mechanistic landscape and offering a tractable RNA-based biomarker/target.
Clinical Implications: circSRSF1 could be developed into a blood-based biomarker for ARDS diagnosis, severity stratification, or monitoring. Therapeutic modulation of circSRSF1 or its downstream effectors warrants exploration.
Key Findings
- circSRSF1 expression is markedly elevated in PBMCs from ARDS patients.
- circSRSF1 levels correlate with WBC count, IL-6, IL-8, and procalcitonin.
- In LPS-stimulated RAW264.7 cells, circSRSF1 inhibition reduces apoptosis and inflammatory responses.
- circSRSF1 knockdown attenuates macrophage M1 polarization, oxidative stress, and ROS generation.
Methodological Strengths
- Combines human PBMC observations with mechanistic in vitro assays.
- Multiple orthogonal readouts (apoptosis, cytokines, polarization, ROS) strengthen biological inference.
Limitations
- Patient cohort size, selection criteria, and longitudinal dynamics are not detailed in the abstract.
- Lack of in vivo validation and incomplete delineation of downstream molecular mechanisms.
Future Directions: Validate circSRSF1 in prospective ARDS cohorts with longitudinal sampling; test causal roles in animal models; map molecular interactors to enable therapeutic targeting.
Acute respiratory distress syndrome (ARDS) is a common respiratory disorder in surgical intensive care units, and its unique pathological features and pathogenesis pose significant health risks to patients. Although circular RNAs have been implicated in various disease processes, their biological functions in ARDS remain largely unexplored. We aimed to investigate the role of circSRSF1 in lipopolysaccharide (LPS)-induced lung injury, thereby providing a basis for biomarker screening and the identification of potential therapeutic targets for ARDS. In this study, we observed a marked increase in circSRSF1 expression in peripheral blood mononuclear cells from patients with ARDS, which correlated with elevated inflammatory markers, including white blood cell counts, interleukin-6 and interleukin-8, and procalcitonin. Using an LPS-induced cell injury model, we demonstrated that inhibiting circSRSF1 in RAW 264.7 cells significantly reduced apoptosis, attenuated inflammatory responses and macrophage M1 polarization, lowered oxidative stress levels, and decreased LPS-induced reactive oxygen species production. These findings suggest that circSRSF1 may play a crucial role in ARDS pathogenesis, with its elevated expression potentially serving as a biomarker for the condition. Overall, circSRSF1 may offer new insights into ARDS development and provide a reference for future clinical research and therapeutic strategies.
3. Association of Obesity With Respiratory Complications in Trauma Patients Undergoing Emergent Surgery.
In a TQIP analysis of 240,120 emergent trauma surgeries, obesity (31.4%) was independently associated with higher respiratory complications (OR 1.43) and mortality (OR 1.11) despite fewer lung injuries. Findings support incorporating obesity into perioperative risk models and proactive airway/ventilation strategies.
Impact: A very large, contemporary registry analysis quantifies the independent respiratory risk conferred by obesity in time-critical trauma operations, a setting with unique airway and ventilation challenges.
Clinical Implications: Include obesity in emergent trauma surgery risk models; anticipate difficult airway, optimize positioning, preoxygenation, lung-protective ventilation, and early VAP prevention; consider enhanced postoperative monitoring.
Key Findings
- N=240,120 emergent trauma surgeries; 31.4% were obese (BMI ≥30).
- Obese patients had fewer lung injuries (17.0% vs 18.8%, P<0.001) but more respiratory complications (3.9% vs 2.7%, P<0.001).
- Adjusted odds of respiratory complications were higher in obesity (OR 1.43, 95% CI 1.36–1.51, P<0.001).
- Adjusted mortality was also higher in obesity (OR 1.11, 95% CI 1.05–1.17, P<0.001).
Methodological Strengths
- Very large national registry with predefined outcomes and multivariable logistic regression.
- Consistent signal across multiple respiratory endpoints including ARDS, VAP, and unplanned intubation.
Limitations
- Retrospective design with potential residual confounding and misclassification.
- Limited granularity on intraoperative ventilation strategies and airway management details.
Future Directions: Prospective validation and implementation studies testing obesity-informed airway/ventilation bundles and predictive models in emergent trauma surgery.
INTRODUCTION: Obesity has been linked to increased mortality and respiratory complications following trauma. However, the association between obesity and respiratory complications in trauma patients undergoing emergent surgery remains unclear. Given the altered respiratory mechanics and airway management difficulties in obese patients, we hypothesized that obesity would be associated with increased respiratory complications and mortality in trauma patients requiring emergent surgery. METHODS: The Trauma-Quality-Improvement-Program database (2017-2022) was queried for trauma patients ≥18-y-old undergoing emergency surgery. Emergency surgery was defined as undergoing an operation within 2 h of arrival. Patients were categorized as obese (BMI ≥30) or non-obese (BMI <30). The primary outcome was respiratory complications, defined as unplanned intubation, ventilator-associated pneumonia, and/or acute respiratory distress syndrome. Bivariate and multivariable logistic regression analyses were performed. RESULTS: From 240,120 patients, 75,386 (31.4%) were obese. Obese patients had a lower rate of lung injuries (17.0% versus 18.8%, P < 0.001) but higher rates of respiratory complications (3.9% versus 2.7%, P < 0.001) and mortality (4.2% versus 3.6%, P < 0.001). After adjusting for covariates, the associated risk of respiratory complications (OR 1.43, CI 1.36-1.51, P < 0.001) and mortality (OR 1.11, CI 1.05-1.17, P < 0.001) were higher for obese patients. CONCLUSIONS: Despite lower rates of lung injuries, obese patients had an increased associated risk of respiratory complications and mortality. Obesity is linked to physiological changes, such as impaired airway management and ventilation, which increase the risk of respiratory issues. These findings highlight the need to include obesity in risk prediction models for trauma patients requiring emergent surgery.